ClinicalTrials.gg
RecruitingNCT06297291US GPSUpdated Nov 20, 2026

Global Paradise System US Post Approval Study

An observational study in Hypertension, Cardiovascular Diseases and Vascular Diseases, sponsored by ReCor Medical, Inc.. Recruiting at 49 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by ReCor Medical, Inc. (part of Otsuka Holdings Co., Ltd.) · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.
Updated Nov 20, 2026Primary completion movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,032 studies in Hypertension with a site in United States — 268 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Planned enrollment
61st of 238
1,000 · median 200
Started
2024
with 92 others
Observational
241 of 2,032
40 open now
Primary completion
2028-12
later than 287 of 367 live
Registered
1,765th of 2,032
by date

Among the 2,032 studies in Hypertension with a site in United States, this one is the 61st largest by planned enrollment of the 238 observational ones that give a count, is one of 93 that started in 2024, is one of 241 observational ones, reaches primary completion later than 287 of the 367 other live ones, and was the 1,765th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

268 of the 2,032 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

263 more — sign in →

All 268 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,032 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.

Read the detailed description

In some patients with high blood pressure, the nerves surrounding the blood vessels leading to the kidneys are overactive, which may cause blood pressure to increase. Renal denervation is a procedure where a catheter is placed inside these blood vessels and heat is used to ablate and disable the nerve activity and lower blood pressure.

Hypertension patients that meet the study eligibility criteria will undergo the ultrasound renal denervation procedure using the Paradise System and will be asked to measure their blood pressure throughout the study, including measuring BP out of the clinic setting using a home BP monitoring device provided by the study. Participants will also be asked to answer some questions about their quality of life, health, sleep and emotions. Additional demographic data, medical history and socio-economic data may also be collected. As part of study participation, everyone who receives ultrasound renal denervation will be seen by the study doctor and designated study team members for 60 months (5 years) following the procedure.

03

Conditions studied

  • Hypertension
  • Cardiovascular Diseases
  • Vascular Diseases

Keywords

  • Blood Pressure
  • Uncontrolled Hypertension
  • Essential Hypertension
  • Resistant Hypertension
  • Renal Denervation
  • Ultrasound Renal Denervation
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control BP will be identified from the general population by the enrolling center.

Subjects enrolled in the RADIANCE CAP study will be transferred to the US GPS study after completion of their 12-month follow-up visit in the RADIANCE CAP study, to complete the remainder of the long-term annual follow-up visits under the post approval study protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated study
  • Documented history of hypertension
  • Documented history of prior or current antihypertensive medication(s)
  • Baseline seated office systolic BP at screening ≥ 140 mmHg
  • Mean pre-procedure home systolic BP of ≥ 135 mmHg
  • Estimated (eGFR) of ≥30 mL/min/m2

RADIANCE CAP patients must provide signed and dated informed consent for inclusion in long-term follow-up. No other criteria are required for inclusion.

Exclusion criteria

Exclusion Criteria:

Patients who meet the following will be excluded from participation:

  • Subject under the age of 18 years old at the time of consent
  • Subject is pregnant prior to index procedure\^ \^ If a treated subject becomes pregnant after ultrasound RDN procedure, the subject will be followed for outcomes.

The ultrasound RDN procedure will be performed according to the IFU for the Paradise System and per the site's standard of care for interventional Procedures.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Prospective Ultrasound Renal Denervation Treatment

    Hypertension patients that meet the eligibility criteria for treatment with Recor Medical Paradise Ultrasound Renal Denervation System will be enrolled and followed post-procedure for 5 years.

    Device: Paradise Ultrasound Renal Denervation Treatment

  • RADIANCE CAP Transfer

    Subjects enrolled in the RADIANCE Continued Access Protocol (CAP) study that are still active and have already completed their post-procedure 12-month follow-up visit are invited to participate in US GPS for long-term annual follow-up visits. These subjects will have already received the ultrasound Renal Denervation treatment under the RADIANCE CAP protocol and will not receive the procedure under the US GPS protocol.

Interventions

  • DeviceParadise Ultrasound Renal Denervation Treatment

    The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure. Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight.

    Also known as: Paradise Ultrasound RDN

06

What researchers measure

Primary outcomes

  1. Co-Primary Endpoint #1: Group Mean BP reduction

    * Ho: Reduction in mean home systolic BP from baseline to 3 months \< 5 mmHg * Ha: Reduction in mean home systolic BP from baseline to 3 months ≥ 5 mmHg

    Time frame: Baseline to 3-months post-procedure

  2. Co-Primary Endpoint #2: Subject Responder

    A subject will be defined as a responder if they achieve any of the following: * Control in home BP (defined as systolic BP \<130 mmHg) at 3 months and/or * Absolute reduction in home systolic BP fall ≥ 5 mmHg at 3 months and/or * Reduction in medication burden measured using defined daily dose (DDD)

    Time frame: Baseline to 3-months post-procedure

Secondary outcomes

  1. Change in mean home systolic/diastolic BP in mmHg

    Time frame: [baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months]

  2. Change in mean office systolic/diastolic BP in mmHg

    Time frame: [baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months]

  3. Change in home and office pulse pressure

    Time frame: [baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months]

  4. Change in the number and/or dosage and/or type of antihypertensive medications taken

    Time frame: [baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months]

  5. Change in patient reported outcomes

    Time frame: [baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months]

  6. Percentage of patients who are controlled as measured by various cut points of home BP (control to be assessed as both < 130 mmHg systolic and <135 mmHg systolic) office BP (control to also be assessed as <130 mmHg and <140 mmHg systolic)

    Time frame: [baseline to 1, 3, 6, 12, 24, 36, 48 and 60 months]

  7. Percentage of patients who demonstrate a reduction in home systolic BP of ≥ 5mmHg, ≥ 10 mmHg and ≥ 15 mmHg

    Time frame: [at 3, 6, 12, 24, 36, 48 and 60 months compared to baseline]

  8. Percentage of patients who demonstrate a reduction in office systolic BP of ≥ 5mmHg, ≥ 10 mmHg and ≥ 15 mmHg

    Time frame: [at 3, 6, 12, 24, 36, 48 and 60 months compared to baseline]

  9. Change in home and office heart rate

    Time frame: [at 3, 6, 12, 24, 36, 48 and 60 months compared to baseline]

07

Study locations

49 of 49 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.

Of 81 industry-sponsored observational studies under Hypertension, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 54 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2028, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 7, 2024
StartActual
Jun 28, 2024
Primary completionEst.
Dec 2028was Sep 2026
CompletionEst.
Jul 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (6 United States)
  • St. Luke's Regional Medical Center · Boise, United States
  • WakeMed Health and Hospitals · Raleigh, United States
  • AHN Saint Vincent · Erie, United States
  • Joseph Maxwell Cleland Atlanta VA Medical Center · Decatur, United States
  • ECU Health Medical Center · Greenville, United States
  • The Heart Hospital - Baylor Plano · Plano, United States
across 2 updates, Oct 16, 2026 – Nov 20, 2026
Primary completion
Sep 2026→Dec 2028
Oct 16, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 2 added, 11 removed
What changed in the criteria
Inclusion criteria
  • EditedMeanBaseline seated office systolic BP at screening ≥ 140 mmHg
Exclusion criteria
  • RemovedPatient lacks appropriate renal anatomy for any treatment with the Paradise Catheter
  • EditedPatientSubject under the age of 18 years old at the time of consent
  • RemovedPatient is pregnant
  • RemovedPatients with transplanted kidney
  • RemovedPresence of abnormal kidney (or secreting adrenal) tumors
  • RemovedTo confirm eligibility for treatment with the Paradise System, the following contraindications listed in the IFU may be determined at the time of procedure prior to treatment:
  • RemovedRenal arteries with diameter < 3mm and > 8mm
  • RemovedRenal artery with fibromuscular dysplasia (FMD)
  • RemovedStented renal artery
  • RemovedRenal artery aneurysm
  • RemovedRenal artery diameter stenosis >30%
  • RemovedIliac/femoral artery stenosis precluding insertion of the Paradise Catheter
  • AddedSubject is pregnant prior to index procedure\^ \^ If a treated subject becomes pregnant after ultrasound RDN procedure, the subject will be followed for outcomes.
  • AddedThe ultrasound RDN procedure will be performed according to the IFU for the Paradise System and per the site's standard of care for interventional Procedures.
Oct 16, 2026
Show all 2 updates
  1. Nov 20, 2026
    3 sites added
    Show 3 added (3 United States)
    • Joseph Maxwell Cleland Atlanta VA Medical Center · Decatur, United States
    • ECU Health Medical Center · Greenville, United States
    • The Heart Hospital - Baylor Plano · Plano, United States
    + 1 other change: verification date
  2. Oct 16, 2026
    3 sites added
    Show 3 added (3 United States)
    • St. Luke's Regional Medical Center · Boise, United States
    • WakeMed Health and Hospitals · Raleigh, United States
    • AHN Saint Vincent · Erie, United States
    Primary completion Sep 2026→Dec 2028
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 2 added, 11 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMeanBaseline seated office systolic BP at screening ≥ 140 mmHg
    Exclusion criteria
    • RemovedPatient lacks appropriate renal anatomy for any treatment with the Paradise Catheter
    • EditedPatientSubject under the age of 18 years old at the time of consent
    • RemovedPatient is pregnant
    • RemovedPatients with transplanted kidney
    • RemovedPresence of abnormal kidney (or secreting adrenal) tumors
    • RemovedTo confirm eligibility for treatment with the Paradise System, the following contraindications listed in the IFU may be determined at the time of procedure prior to treatment:
    • RemovedRenal arteries with diameter < 3mm and > 8mm
    • RemovedRenal artery with fibromuscular dysplasia (FMD)
    • RemovedStented renal artery
    • RemovedRenal artery aneurysm
    • RemovedRenal artery diameter stenosis >30%
    • RemovedIliac/femoral artery stenosis precluding insertion of the Paradise Catheter
    • AddedSubject is pregnant prior to index procedure\^ \^ If a treated subject becomes pregnant after ultrasound RDN procedure, the subject will be followed for outcomes.
    • AddedThe ultrasound RDN procedure will be performed according to the IFU for the Paradise System and per the site's standard of care for interventional Procedures.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06297291
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Jun 28, 2024
Primary completion
Dec 2028 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Helen Reeve-Stoffer, PhD
Contact
hreeve-stoffer@recormedical.com
+1 650-912-9032

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion